Insulin-like growth factor-1 receptor and ligand targeting in head and neck squamous cell carcinoma

Cancer Letters

Volumn 248, Issue 2, 2007, Pages 269-279

  Slomiany, Mark G ^a   Black, Leigh Ann ^a   Kibbey, Megan M ^a   Tingler, Melissa A ^a   Day, Terry A ^a   Rosenzweig, Steven A ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

AG1478; Epidermal growth factor; Head and neck squamous cell carcinoma; Insulin like growth factor binding protein 3; Insulin like growth factor 1 receptor; NVP AEW541; Receptor tyrosine kinase inhibitors

Indexed keywords

4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; EPIDERMAL GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; NVP AEW 541; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN TYROSINE KINASE INHIBITOR; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; THYMIDINE; UNCLASSIFIED DRUG;

ARTICLE; CANCER RISK; CELL CYCLE S PHASE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; STIMULATION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL PROLIFERATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOBLOTTING; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; LIGANDS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, IGF TYPE 1;

EID: 33847271170     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2006.08.004     Document Type: Article

References (37)

1. Canto M.T., and Devesa S.S. Oral cavity and pharynx cancer incidence rates in the United States. Oral. Oncol. 38 (2002) 610-617
2. Solomon D.S., Brandt R., Ciardiello F., and Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev. Oncol. Hematol. 19 (1995) 183-232
3. Davies D.E., and Chamberlin S.G. Targeting the epidermal growth factor receptor for therapy of carcinomas. Biochem. Pharmacol. 51 (1996) 1101-1110
4. Rusch V., Mendelsohn J., and Dmitrovsky E. The epidermal growth factor receptor and its ligands as therapeutic targets in human tumors. Cytokine Growth Factor Rev. 7 (1996) 133-141
5. Grandis J.R., Chakraborty A., Zheng Q., Melhem M.F., and Tweardy D.J. Downmodulation of TGF-alpha protein expression with antisense oligonucleotides inhibits proliferation of head and neck squamous carcinoma but not normal mucosal epithelial cells. J. Cell Biochem. 69 (1998) 55-62
6. Wirth L.J., Haddad R.J., Lindeman N.I., Zhao X., Lee J.C., Joshi V.A., Norris Jr. C.M., and Posner M.R. Phase I study of gefitinib plus celecoxib in recurrent or metastatic squamous cell carcinoma of the head and neck. J. Clin. Oncol. 23 (2005) 6976-6981
7. Baselga J. Monoclonal antibodies directed at growth factor receptors. Ann. Oncol. 11 Suppl. 3 (2000) 187-190
8. Garber K. Tyrosine kinase inhibitor research presses on despite halted clinical trial. J. Natl. Cancer Inst. 92 (2000) 967-969
9. Rosenzweig S.A. What's new in the IGF-binding proteins?. Growth Horm. IGF Res. 14 (2004) 329-336
10. Firth S.M., and Baxter R.C. Cellular actions of the insulin-like growth factor binding proteins. Endocr. Rev. 23 (2002) 824-854
11. Wu X., Zhao H., Do K.-A., Johnson M.M., Dong Q., Hong W.K., and Spitz M.R. Serum levels of insulin growth factor (IGF-1) and IGF-binding protein predict risk of second primary tumors in patients with head and neck cancer. Clin. Cancer Res. 10 (2004) 3988-3995
12. Hankinson S.E., Willet W.C., Colditz G.A., Hunter D.J., Michaud D.S., Deroo B., Rosner B., Speizer F.E., and Pollak M. Circulating concentrations of insulin-like growth factor-1 and risk of breast cancer. Lancet 351 (1998) 1393-1396
13. Chan J.M., Stampfer M.J., Giovannucci E., Gann P.H., Ma J., Wilkinson P., Hennekens C.H., and Pollak M. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 279 (1998) 563-566
14. H. Yu, M.R. Spitz, J. Mistry, J. Gu, W.K. Hong, X. Wu, Plasma levels of insulin-like growth factor-1 and lung cancer risk: a case-control study, 91 (1999) 151-156.
15. Ma J., Pollak M.N., Giovannucci E., Chan J.M., Tao Y., Hennekens C.H., and Stampfer M.J. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-1 and IGF-binding protein-3. J. Natl. Cancer Inst. 91 (1999) 620-625
16. Papadimitrakopoulou V.A., Brown E.N., Liu D.D., El-Naggar A.K., Lee J.J., Hong W.K., and Lee H.-Y. The prognostic role of loss of insulin-like growth factor-binding protein-3 expression in head and neck carcinogenesis. Cancer Let. (2005)
17. Rosenfeld R.G., Lamson G., Pham H., Oh Y., Conover C., De Leon D.D., Donovan S.M., Ocrant I., and Giudice L. Insulin-like growth factor-binding proteins. Recent Prog. Horm. Res. 46 (1990) 99-159 discussion 159-163
18. Krywichi R.F., and Yee D. The insulin-like growth factor family of ligands, receptors, and binding proteins. Breast Cancer Res. Treat. 22 (1992) 7-19
19. Chang Y.S., Wang L., Suh Y.-A., Mao L., Karpen S.J., Khuri F.R., Hong W.K., and Lee H.-Y. Mechanisms underlying lack of insulin-like growth factor-binding protein-3 expression in non-small-cell lung cancer. Oncogene 23 (2004) 6569-6580
20. Garcia-Echeverria C., Pearson M.A., Marti A., Meyer T., Mestan J., Zimmermann J., Gao J., Brueggen J., Capraro H.G., Cozens R., Evans D.B., Fabbro D., Furet P., Porta D.G., Liebetanz J., Martiny-Baron G., Ruetz S., and Hofmann F. In vivo antitumor activity of NVP-AEW541- A novel, potent, and selective inhibitor of the IGF-IR kinase. Cancer Cell. 5 (2004) 231-239
21. Kuribayashi A., Kataoka K., Kurabayashi T., and Miura M. Evidence that basal activity, but not transactivation, of the epidermal growth factor receptor tyrosine kinase is required for insulin-like growth factor 1-induced activation of extracellular signal-regulated kinase in oral carcinoma cells. Endocrinology 145 (2004) 4976-4984
22. Zhang Q., Thomas S.M., Lui V.W.Y., Xi S., Siegfried J.M., Fan H., Smithgall T.E., Mills G.B., and Grandis J.R. Phosphorylation of TNF-{alpha} converting enzyme by gastrin-releasing peptide induces amphiregulin release and EGF receptor activation. Proc. Natl. Acad. Sci. USA 103 (2006) 6901-6906
23. Ahmad T., Farnie G., Bundred N.J., and Anderson N.G. The mitogenic action of insulin-like growth factor I in normal human mammary epithelial cells requires the epidermal growth factor receptor tyrosine kinase. J. Biol. Chem. 279 (2004) 1713-1719
24. Knowlden J.M., Hutcheson I.R., Barrow D., Gee J.M.W., and Nicholson R.I. Insulin-like growth factor-1 receptor signaling in tamoxifen-resistant breast cancer: A supporting role to the epidermal growth factor receptor. Endocrinology 146 (2005) 4609-4618
25. Kibbey M.M., Jameson M.J., Eaton E.M., and Rosenzweig S.A. Insulin-like growth factor binding protein-2: contributions of the C-terminal domain to insulin-like growth factor-1 binding. Mol. Pharmacol. 69 (2006) 833-845
26. Rheinwald J.G., and Beckett M.A. Tumorigenic keratinocyte lines requiring anchorage and fibroblast support cultured from human squamous cell carcinomas. Cancer Res. 41 (1981) 1657-1663
27. Carey T.E., Kimmel K.A., Schwartz D.R., Richter D.E., Baker S.R., and Krause C.J. Antibodies to human squamous cell carcinoma. Otolaryngol. Head Neck Surg. 91 (1983) 482-491
28. Rangan S.R. A new human cell line (FaDu) from a hypopharyngeal carcinoma. Cancer 29 (1972) 117-121
29. Robinson S.A., and Rosenzweig S.A. Synthesis and characterization of biotinylated forms of insulin-like growth factor-1: topographical evaluation of the IGF-1/IGFBP-2 and IGFBP-3 interface. Biochemistry 43 (2004) 11533-11545
30. Slomiany M.G., and Rosenzweig S.A. IGF-1 induced VEGF and IGFBP-3 secretion correlates with increased Hif-1 alpha expression and activity in retinal pigment epithelial cell line D407. Invest. Ophthalmol. Vis. Sci. 45 (2004) 2838-2847
31. Robinson S.A., and Rosenzweig S.A. Paradoxical effects of the phage display-derived peptide antagonist IGF-F1-1 on insulin-like growth factor-1 receptor signaling. Biochem. Pharmacol. 72 (2006) 53-61
32. Steller M.A., Delgado C.H., Bartels C.J., Woodworth C.D., and Zou Z. Overexpression of the insulin-like growth factor-1 receptor and autocrine stimulation in human cervical cancer cells. Cancer Res. 56 (1961) 1761-1765
33. Slomiany M.G., Black L.A., Kibbey M.M., Day T.A., and Rosenzweig S.A. IGF-1 induced vascular endothelial growth factor secretion in head and neck squamous cell carcinoma. Biochem. Biophys. Res. Commun. 342 (2006) 851-858
34. Benini S., Zuntini M., Manara M.C., Cohen P., Nicoletti G., Nanni P., Oh Y., Picci P., and Scotlandi K. Insulin-like growth factor binding protein 3 as an anticancer molecule in Ewing's Sarcoma. Int. J. Cancer. 119 (2006) 1046-1049
35. Ali O., Cohen P., and Lee K.W. Epidemiology and biology of insulin-like growth factor binding protein-3 (IGFBP-3) as an anti-cancer molecule. Horm. Metab. Res. 35 (2003) 726-733
36. Miyamoto S.I., Yano K., Sugimoto S., Ishii G., Hasebe T., Endoh Y., Kodama K., Goya M., Chiba T., and Ochiai A. Matrix metalloproteinase-7 facilitates insulin-like growth factor bioavailability through Its proteinase activity on insulin-like growth factor binding protein 3. Cancer Res. 64 (2004) 665-671
37. Hemers E., Duval C., McCaig C., Handley M., Dockray G.J., and Varro A. Insulin-like growth factor binding protein-5 Is a target of matrix metalloproteinase-7: Implications for epithelial-mesenchymal signaling. Cancer Res. 65 (2005) 7363-7369